T-cell clones persisting in the circulation after autologous hematopoietic SCT are undetectable in the peripheral CD34+ selected graft

Bone Marrow Transplantation

Volumn 45, Issue 2, 2010, Pages 325-331

  Dubinsky, A N ^a,b   Burt, R K ^c   Martin, R ^a,d   Muraro, P A ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Clinical Multiple Sclerosis Research   (Germany)

Author keywords

Autoimmune disease; Autologous hematopoietic SCT; Multiple sclerosis; T cells; TCRs

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; T LYMPHOCYTE RECEPTOR;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD34 SELECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CLONING; CELL RENEWAL; CELL SURVIVAL; CONTROLLED STUDY; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; HUMAN CELL; MULTIPLE SCLEROSIS; MYELOABLATIVE CONDITIONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD34; CLONE CELLS; COMPLEMENTARITY DETERMINING REGIONS; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE SCLEROSIS; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS;

EID: 76749085197     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.139     Document Type: Article

References (22)

1. Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature 2005; 435: 620-627.
2. Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201: 805-816.
3. De Kleer I, Vastert B, Klein M, Teklenburg G, Arkesteijn G, Yung GP et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4CD25 immune regulatory network. Blood 2006; 107: 1696-1702.
4. Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006; 54: 3750-3760.
5. Openshaw H, Lund BT, Kashyap A, Atkinson R, Sniecinski I, Weiner LP et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000; 6: 563-575.
6. Ni XS, Ouyang J, Zhu WH, Wang C, Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant 2006; 20: 485-489.
7. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003; 102: 2364-2372.
8. Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 2003; 9: 583-591.
9. Samijn JP, Te Boekhorst PA, Mondria T, Van Doorn PA, Flach HZ, Van Der Meche FG et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 46-50.
10. Burt RK, Cohen BA, Russell E, Spero K, Joshi A, Oyama Y et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003; 102: 2373-2378.
11. Muraro PA, Jacobsen M, Necker A, Nagle JW, Gaber R, Sommer N et al. Rapid identification of local T cell expansion in inflammatory organ diseases by flow cytometric T cell receptor Vbeta analysis. J Immunol Methods 2000; 246: 131-143.
12. Van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317.
13. Packer AN, Muraro PA. Optimized clonotypic analysis of T-cell receptor repertoire in immune reconstitution. Exp Hematol 2007; 35: 516-521.
14. Pette M, Gold R, Pette DF, Hartung HP, Toyka KV. Mafosfamide induces DNA fragmentation and apoptosis in human T-lymphocytes. A possible mechanism of its immunosuppressive action. Immunopharmacology 1995; 30: 59-69.
15. Strauss G, Westhoff MA, Fischer-Posovszky P, Fulda S, Schanbacher M, Eckhoff SM et al. 4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG. Cell Death Differ 2007; 15: 342-343.
16. Kalina T, Lu H, Zhao Z, Blewett E, Dittmer DP, Randolph- Habecker J et al. De novo generation of CD4 T cells against viruses present in the host during immune reconstitution. Blood 2005; 105: 2410-2414.
17. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P. A direct estimate of the human alphabeta T cell receptor diversity. Science 1999; 286: 958-961.
18. Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel Met al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002; 46: 2301-2309.
19. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387-1394.
20. Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005; 35: 3332-3342.
21. Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008; 7: 626-636.
22. Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009; 8: 244-253.